Subekti Imam, Boedisantoso Asman, Moeloek Nila Djuwita, Waspadji Sarwono, Mansyur Muchtaruddin
Department of Internal Medicine, Faculty of Medicine, University of Indonesia - Cipto Mangunkusumo Hospital. Jl. Diponegoro no. 71, Jakarta Pusat 10430, Indonesia.
Acta Med Indones. 2012 Apr;44(2):114-21.
to evaluate the association between TSH receptor antibody (TRAb), thyroid stimulating antibody (TSAb), and thyroid stimulation blocking antibody (TBAb) and TSAb/TBAb ratio with clinical activity score (CAS) and degree of severity of GO.
this was a cross sectional study involving 75 consecutive Graves' disease patients admitted at Cipto Mangunkusumo hospital between December 2009 until January 2011. Bartley criteria were used as clinical criteria for GO. In addition to clinical criteria, orbital CT scan and measurement of extraocular muscle thickness and increment of retroorbital fat volume were carried out. Furthermore, TSH, FT4, FT3 and TRAb were measured using ELISA method, TSAb and TBAb using RIA method. Clinical activity of GO was measured using clinical activity score (CAS). Degree of severity of GO was measured using Eckstein modified NOSPECS system.
subjects consisted of various different ethnic groups in Indonesia, with the range of age between 20-63 years old. There were 28 (37%) and 61 (83.6%) GO subjects with clinical-based and CT scan-based respectively. Among all GD subjects, the proportion of TSAb were 70 (93.3%) and TBAb were 13 (17.3%). There was no correlation between TRAb and CAS nor the severity of GO, either clinical-based and CT scan-based GO. There was also no correlation between TSAb and CAS. No correlation between TSAb and severity of CT scan-based GO, but significant correlation between TSAb and severity of clinical-based GO (r=0.274; p=0.009) was noted. There was no correlation between TBAb and severity of GO. We also found no correlation between TBAb and CAS of clinical-based GO, but we found strong negative correlation with CAS CT scan-based GO (r=-0.565; p=0.035). The TSAb/TBAb ratio was also strongly correlated with all parameters evaluated, CAS of clinical-based GO (r=0.730; p=0.031), CAS of CT scan-based GO (r=0.607; p=0.024), degree of severity of clinical-based GO (r=0.563; p=0.023), and degree of severity of CT scan-based GO (r=0.762; p=0.001).
TRAb was not correlated with CAS and degree of severity of clinical-based and CT scan-based GO, while TSAb was correlated with degree of severity of GO. There was negative correlation between TBAb and CAS of clinical-based GO, whereas TSAb/TBAb ratio was correlated with CAS and degree of severity of both clinical-based and CT scan-based GO.
评估促甲状腺素受体抗体(TRAb)、甲状腺刺激抗体(TSAb)和甲状腺刺激阻断抗体(TBAb)以及TSAb/TBAb比值与临床活动评分(CAS)和GO严重程度之间的关联。
这是一项横断面研究,纳入了2009年12月至2011年1月期间在西爪哇省芝多尼曼古苏莫医院连续收治的75例格雷夫斯病患者。采用巴特利标准作为GO的临床标准。除临床标准外,还进行了眼眶CT扫描以及眼外肌厚度测量和眶后脂肪体积增加量的测量。此外,采用酶联免疫吸附测定法(ELISA)测量促甲状腺激素(TSH)、游离甲状腺素(FT4)、游离三碘甲状腺原氨酸(FT3)和TRAb,采用放射免疫分析法(RIA)测量TSAb和TBAb。采用临床活动评分(CAS)评估GO的临床活动度。采用埃克斯坦改良的NOSPECS系统评估GO的严重程度。
研究对象包括印度尼西亚不同的种族群体,年龄范围在20 - 63岁之间。分别有28例(37%)和61例(83.6%)GO患者基于临床诊断和基于CT扫描诊断。在所有格雷夫斯病患者中,TSAb的比例为70例(93.3%),TBAb的比例为13例(17.3%)。TRAb与CAS以及基于临床诊断和基于CT扫描诊断的GO严重程度均无相关性。TSAb与CAS也无相关性。TSAb与基于CT扫描诊断的GO严重程度无相关性,但与基于临床诊断的GO严重程度存在显著相关性(r = 0.274;p = 0.009)。TBAb与GO严重程度无相关性。我们还发现TBAb与基于临床诊断的GO的CAS无相关性,但与基于CT扫描诊断的GO的CAS存在强负相关性(r = -0.565;p = 0.035)。TSAb/TBAb比值与所有评估参数也存在强相关性,包括基于临床诊断的GO的CAS(r = 0.730;p = 0.031)、基于CT扫描诊断的GO的CAS(r = 0.607;p = 0.024)、基于临床诊断的GO的严重程度(r = 0.563;p = 0.023)以及基于CT扫描诊断的GO的严重程度(r = 0.762;p = 0.001)。
TRAb与基于临床诊断和基于CT扫描诊断的GO的CAS及严重程度均无相关性,而TSAb与GO严重程度相关。TBAb与基于临床诊断的GO的CAS呈负相关,而TSAb/TBAb比值与基于临床诊断和基于CT扫描诊断的GO的CAS及严重程度均相关。